Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Xilio Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- +1 vs. Q1 2024
- Shares held
- 14.5M
- +2.04M (+16.3%) vs. Q1 2024
- Total value
- $13.7M
- +$270.2K (+2.0%) vs. Q1 2024
- New holders
- 7
- 9 more added
- Sold out
- 6
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 3,785,450 | $3.59M | 0.39% | +980,037+34.9% | Added |
| Rock Springs Capital Management LP | 3,003,259 | $2.85M | 0.09% | +1,562,500+108.4% | Added |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.40M | 0.60% | 00.0% | Unchanged |
| RiverVest Venture Management LLC | 1,441,444 | $1.37M | 20.01% | 00.0% | Unchanged |
| FMR LLC | 1,395,853 | $1.32M | 0.00% | −511,818−26.8% | Reduced |
| Morgan Stanley | 1,112,740 | $1.05M | 0.00% | +890,835+401.4% | Added |
| Vanguard Group Inc | 902,531 | $855.1K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 295,000 | $279.5K | 0.00% | +45,554+18.3% | Added |
| Balyasny Asset Management LLC | 272,486 | $258.2K | 0.00% | −66,056−19.5% | Reduced |
| FIL Ltd | 218,705 | $207.2K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 182,855 | $173.3K | 0.00% | +98,029+115.6% | Added |
| Bridgeway Capital Management, LLC | 71,081 | $67.3K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 66,418 | $62.9K | 0.00% | +21,063+46.4% | Added |
| State Street Corp | 43,390 | $41.1K | 0.00% | +27,700+176.5% | Added |
| SevenBridge Financial Group, LLC | 41,000 | $37.2K | 0.01% | +10,000+32.3% | Added |
| Northern Trust Corp | 39,208 | $37.1K | 0.00% | +21,410+120.3% | Added |
| Raymond James & Associates | 38,825 | $36.8K | 0.00% | +38,825 | New |
| XTX Topco Ltd | 33,289 | $31.5K | 0.00% | +33,289 | New |
| Avantax Planning Partners, Inc. | 25,000 | $23.7K | 0.00% | +25,000 | New |
| Two Sigma Securities, LLC | 13,271 | $12.6K | 0.00% | +13,271 | New |
| Millennium Management LLC | 12,205 | $11.6K | 0.00% | −57,993−82.6% | Reduced |
| Charles Schwab Investment Management Inc | 11,925 | $11.3K | 0.00% | 00.0% | Unchanged |
| Dunhill Financial, LLC | 10,274 | $9.73K | 0.01% | 00.0% | Unchanged |
| Pinnacle Financial Group, LLC | 10,000 | $9.47K | 0.00% | +10,000 | New |
| Tower Research Capital LLC (TRC) | 4,207 | $3.99K | 0.00% | −6,946−62.3% | Reduced |
| ADAR1 Capital Management, LLC | 1,500 | $1.42K | 0.00% | +1,500 | New |
| Key Financial Inc | 830 | $786 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 692 | $656 | 0.00% | +692 | New |
| UBS Group AG | 201 | $191 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 59 | $56 | 0.00% | −2,685−97.8% | Reduced |
| Qube Research & Technologies Ltd | 4 | $4 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 366 | $0 | 0.00% | −167−31.3% | Reduced |
| Atlas Venture Life Science Advisors, LLC | 0 | $0 | 0.00% | −992,912−100.0% | Sold out |
| PFG Investments, LLC | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −29,500−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −27,500−100.0% | Sold out |
| Summit Trail Advisors, LLC | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −108−100.0% | Sold out |